Accession Number : AD1048522


Title :   Urinary Protein Biomarker Analysis


Descriptive Note : Technical Report,30 Sep 2016,29 Sep 2017


Corporate Author : University of Washington Seattle United States


Personal Author(s) : Liu, Alvin Y


Full Text : http://www.dtic.mil/dtic/tr/fulltext/u2/1048522.pdf


Report Date : 01 Oct 2017


Pagination or Media Count : 101


Abstract : Targeted mass spectrometry proteomics was developed (identifying the most suitable surrogate peptides) to measure a set of proteins secreted by cell types of prostate tumors in voided urine. These cancer-associated protein biomarkers were identified by transcriptomic comparison of cancer cells vs. normal luminal cells; cancer-associated stromal cells vs. normal stromal cells. The assays allow quantification of many markers simultaneously in the same bio specimens. Using the levels of PSA for normalization, the multimarker panel achieved an AUC of 0.95 (specificity 1,sensitivity 0.86) in distinguishing cancer from non-cancer. Furthermore, levels of marker MMP9 can be used to distinguish significant cancer from low-risk cancer because MMP9 shows an increased expression in Gleason pattern 4 tumor glands than pattern 3 tumor glands. Biomarker measurements by mass spectrometry and ELISA were in good agreement so that a multiplex ELISA could be developed in the future. Urine collection from patient donors is simple and does not require a digital rectal exam so that donations can be given multiple times with minimal risk since urine is a natural waste product. Antibodies developed for biomarker ELISA can also be used in cancer therapy, especially for a marker(AGR2) that is on the cell surface of cancer cells but inside of normal cells.


Descriptors :   Prostate cancer , biological markers , biological detection , proteins , metastasis , tumor cell line , gene expression , mass spectrometry , antigens


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE